Cargando…

Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis

PURPOSE: Fenebrutinib (GDC-0853), a Bruton’s tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clinical trial in patients with rheumatoid arthritis (RA). Our aim was to apply a model-informed drug development (MIDD) approach to examine the totality of available clinical efficacy data. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Phyllis, Yu, Jiajie, Chinn, Leslie, Prohn, Marita, Huisman, Jan, Matzuka, Brett, Hanley, William, Tuckwell, Katie, Quartino, Angelica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944649/ https://www.ncbi.nlm.nih.gov/pubmed/31907670 http://dx.doi.org/10.1007/s11095-019-2752-y

Ejemplares similares

Understanding the Effect of Hydroxypropyl‐β‐Cyclodextrin on Fenebrutinib Absorption in an Itraconazole–Fenebrutinib Drug–Drug Interaction Study
por: Durk, Matthew R., et al.
Publicado: (2020)

Physiologically‐Based Pharmacokinetic Model‐Informed Drug Development for Fenebrutinib: Understanding Complex Drug‐Drug Interactions
por: Chen, Yuan, et al.
Publicado: (2020)

Complex DDI by Fenebrutinib and the Use of Transporter Endogenous Biomarkers to Elucidate the Mechanism of DDI
por: Jones, Nicholas S., et al.
Publicado: (2019)

Fenebrutinib Versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double‐Blind, Phase II Trial
por: Cohen, Stanley, et al.
Publicado: (2020)

Fenebrutinib in H(1) antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial
por: Metz, Martin, et al.
Publicado: (2021)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

622. Population Pharmacokinetic Analysis and Probability of Target Attainment Simulations of Pivmecillinam for the Treatment of Uncomplicated Urinary Tract Infection
por: Santerre Henriksen, Anne Laurence, et al.
Publicado: (2022)

Investigation of Fenebrutinib Metabolism and Bioactivation Using MS(3) Methodology in Ion Trap LC/MS
por: Alsibaee, Aishah M., et al.
Publicado: (2023)

Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021)

Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis
por: Welsh, Paul, et al.
Publicado: (2016)

Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis
por: Toyoshima, Junko, et al.
Publicado: (2020)

Regional variations in adverse event reporting rates and ACR responses in placebo/standard-of-care arms of rheumatoid arthritis trials
por: Keebler, Daniel, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection
por: Zhu, Li, et al.
Publicado: (2018)

Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2017)

Population pharmacokinetics of bevacizumab in cancer patients with external validation
por: Han, Kelong, et al.
Publicado: (2016)

Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors
por: Krishnatry, Anu Shilpa, et al.
Publicado: (2021)

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
por: Kang, Jia, et al.
Publicado: (2020)

Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients
por: Prohn, Marita, et al.
Publicado: (2021)

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
por: Gabay, Cem, et al.
Publicado: (2016)

Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation
por: Han, Kelong, et al.
Publicado: (2015)

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
por: Strand, Vibeke, et al.
Publicado: (2017)

Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician
por: Abdel-Rahman, Susan M., et al.
Publicado: (2016)

Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects
por: Yang, Haijing, et al.
Publicado: (2022)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor
por: Chan, Phyllis, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer’s disease
por: Yoshida, Kenta, et al.
Publicado: (2020)

Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia
por: Galluppi, Gerald R., et al.
Publicado: (2021)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Potentially Critical Driving Situations During “Blue-light” Driving: A Video Analysis
por: Prohn, Maria J., et al.
Publicado: (2023)

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
por: Quartino, Angelica L., et al.
Publicado: (2015)

Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
por: Wang, Bei, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects
por: Jeong, Seung-Hyun, et al.
Publicado: (2020)

Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects
por: Jeong, Seung-Hyun, et al.
Publicado: (2021)

Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
por: Narasimhan, Narayana I, et al.
Publicado: (2013)

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
por: Gale, Sara, et al.
Publicado: (2019)

Population Pharmacokinetic Analysis of Rivipansel in Healthy Subjects and Subjects with Sickle Cell Disease
por: Nayak, Satyaprakash, et al.
Publicado: (2021)

Population Pharmacokinetics and Exposure‐Response Relationships of Astegolimab in Patients With Severe Asthma
por: Kotani, Naoki, et al.
Publicado: (2022)

Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I–III Clinical Trials
por: Klünder, Ben, et al.
Publicado: (2019)

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin(®)), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors
por: Quartino, Angelica L., et al.
Publicado: (2018)

Safety, Tolerability, and Pharmacokinetics of Ibuprofenamine Hydrochloride Spray (NSAIDs), a New Drug for Rheumatoid Arthritis and Osteoarthritis, in Healthy Chinese Subjects
por: Xie, Panpan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5fd2ehrh9aj10ukt2eooglifgf